Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for preventing or treating aging-related diseases containing decursin derivative as active ingredient

A technology for disease prevention and active ingredients, which is applied in the field of pharmaceutical compositions for the prevention or treatment of aging-related diseases containing a presenilin derivative as an active ingredient, can solve the problems of side effects, hindering the farnesylation of progerin, and the like, Achieve the effect of increasing collagen production, excellent presenilin expression and

Active Publication Date: 2019-12-13
PRG S&TECH INC
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Therefore, as a method for the treatment of progeria, there are methods for preventing the farnesylation of presenilin, or using autophagy (autophage) to remove farnesylated lamin A to reduce presenilin, but this There are side effects in both cases, and so far there has been no report on a method that can fundamentally treat progeria

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing or treating aging-related diseases containing decursin derivative as active ingredient
  • Pharmaceutical composition for preventing or treating aging-related diseases containing decursin derivative as active ingredient
  • Pharmaceutical composition for preventing or treating aging-related diseases containing decursin derivative as active ingredient

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment

[0053] Hereinafter, to facilitate understanding, the following examples will be used in detail. However, the following examples are only for illustrating the content of the present invention, and the scope of the present invention is not limited by these examples. The embodiments of the present invention are provided to enable those skilled in the art to understand the present invention more completely.

[0054] Reference example: materials and equipment

[0055] 1 H and 13 The C NMR spectrum was measured using a JNM-AL 400 spectrometer (400MHz, JEOL, Japan), the melting point (Meltingpoint) was measured using an Electrothermal melting point apparatus (Yamaco.MD-S3), and the mass analysis instrument used an API 2000LC / MS / MS spectrometer (PE Sciex, Canada).

[0056] In addition, the optical rotations (Optical rotations) were measured by JASCO DIP-360 automatic digital polarimeter, and the purity of chiral substances was measured by HPLC (Shinadzu LC-6AD, Japan), chromatogr...

Embodiment 1

[0059]Example 1: Synthesis of (+)-Decursin Derivatives of Ether-form (SLC-D011)

[0060] (7S)-(+)-8,8-dimethyl-7-(3-phenyl-allyloxy)-7,8-dihydro-6H was synthesized according to the same process of the following reaction formulas 1 and 2 -pyrano[3,2-g]chromene-2-one ((7S)-(+)-8,8-dimethyl-7-(3-phenyl-allyoxy)-7,8-dihydro-6H- pyrano[3,2-g]chromen-2-one (SLC-D011)).

[0061] 1. Synthesis process I

[0062] Reaction 1

[0063]

[0064] Step I: add trans-cinnamic acid (trans-cinnamic acid, D011a, 5g, 33.7mmol) in the 100ml round bottom flask after dissolving with methanol (50ml), drop 5 drops of concentrated H 2 SO 4 , heated to reflux at 80°C for 24 hours, the reaction mixture was cooled to room temperature and then concentrated under reduced pressure.

[0065] Thereafter, liquid separation was performed with dichloromethane (300 ml) and distilled water (300 ml), and the organic layer was collected, dehydrated with sodium sulfate, and filtered.

[0066] The filtrate obtai...

Embodiment 2

[0092] Example 2: Confirmation of the effect of SLC-D011 as a nuclear lamin A (LMNA)-presenilin binding inhibitor

[0093] 1. Animal experiments

[0094] Animal experiments were carried out in accordance with the animal policy recognized by Pusan ​​National University, in the certification evaluation association and laboratory animal management certification organization.

[0095] Heterozygous Lmna provided by Carlos Lopez-Otin (University of Oviedo, Oviedo, Asturias, Spain) + / G609G Proper mating of Lmna G609G / 609G .

[0096] SLC-D011 20 mg / kg mixed with DMOS and PBS was intraperitoneally injected twice a week into 5-week-old mice. In addition, SLC-D011 dissolved in an olein-based solution (olein-based solution) at a concentration of 10 mg / ml was orally administered to mice five times a week, and mice in the control group were given only A solution based on glyceryl oleate.

[0097] Lmna G609G / 609G Mice were dosed starting at 5 weeks of age and treated with fresh compoun...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a novel decursin derivative and a composition for preventing or treating aging-related diseases containing the same as an active ingredient. The novel decursin derivative has exhibited an excellent effect of inhibiting progerin expression and an excellent effect of inhibiting binding between progerin and lamin A, and it has been confirmed that the novel decursin derivative prolongs the survival period of animal models in which progeria is induced. Therefore, a compound of the present invention can be effectively used for the prevention or treatment of aging-related diseases such as progeria, etc.

Description

technical field [0001] The present invention relates to a novel proscurdin derivative and a composition for preventing or treating aging-related diseases containing the same as an active ingredient. Background technique [0002] As the lifespan of human beings increases, people pay more and more attention to the process of aging, but there are many parts that are not yet clear. Recent research has mainly focused on the genetic or molecular aging mechanism of human progeria. [0003] Progeria or Hutchinson-Gilford Progeria syndrome (Hutchinson-Gilford Progeria syndrome) is a fatal and rare genetic disorder in which early aging occurs in children. In children with Progeria, early childhood shows Normal appearance, but severe growth retardation after 9 to 24 months, eventually showing symptoms of short stature and light weight. Characteristic face shape, atherosclerosis, cardiovascular system disease, stroke, hip dislocation, etc.; loss of subcutaneous fat layer; nail defects;...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D493/04A61K31/37
CPCA61K31/37C07D493/04A61P17/00A61P3/00A61Q19/08A61K8/498A61K45/06A61P43/00
Inventor 朴范埈宋圭镛吴柔锡李智贤尹殷周
Owner PRG S&TECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com